Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/kjm2.12531 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.
Allergy
December 2024
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Background: Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut allergy.
Methods: A Phase II, 24-week, multicenter, single-arm, open-label, proof-of-concept study was conducted in the USA and Canada (NCT03793608).
Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis.
J Allergy Clin Immunol
August 2024
Sanofi, Madrid, Spain.
Article Synopsis
- Pediatric patients with moderate-to-severe atopic dermatitis (AD) showed elevated inflammatory biomarkers, which dupilumab treatment aimed to reduce.
- In a study involving various age groups, patients received either dupilumab or a placebo, leading to significant reductions in biomarkers such as TARC/CCL17, total IgE, and lactate dehydrogenase (LDH) after 16 weeks.
- The results indicate that dupilumab effectively minimizes inflammation in these patients, reaching levels similar to healthy individuals.
Rate of dupilumab use and symptom severity of patients with chronic rhinosinusitis with nasal polyposis after Draf 3 frontal sinusotomy.
Int Forum Allergy Rhinol
December 2024
Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus Surgery, Oregon Health & Science University, Portland, Oregon, USA.
Background: The indications for endoscopic modified Lothrop procedure (Draf 3) in patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP) remain unclear. This study evaluates the effectiveness of Draf 3 for refractory CRSwNP focusing on improvements in disease severity and need for subsequent dupilumab rescue therapy.
Methods: Retrospective review of patients with CRSwNP undergoing Draf 3 surgery at a tertiary center between 2012 and 2022.
Dupilumab Improves Facial Pain and Reduces Rescue Treatments in Patients with CRSwNP and Recalcitrant Frontal Sinusitis.
J Pers Med
July 2024
Unit of Otorhinolaryngology and Head-Neck Surgery, "A. Gemelli" University Hospital Foundation IRCCS, 00168 Rome, Italy.
Recalcitrant frontal sinusitis in patients with chronic rhinosinusitis and nasal polyps (CRSwNP) has a negative impact on their quality of life due to frontal pain and a high risk of sinus occlusion, thus necessitating antibiotics, systemic corticosteroids, and multiple surgeries. The aim of this study was to assess the efficacy of dupilumab in reducing frontal pain and the need for rescue treatments for recalcitrant frontal sinusitis in patients with CRSwNP. We enrolled a cohort of 10 patients with severe uncontrolled CRSwNP and concomitant recurrent frontal sinusitis associated with severe facial pain measured by MIDAS score who were treated with dupilumab 300 mg every 2 weeks and followed for at least 12 months.
View Article and Find Full Text PDFReal-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up.
Rhinology
August 2024
St. John's Hospital, Department of Otorhinolaryngology and Maxillofacial Surgery, Budapest, Hungary.
Background: Research on the immune mechanism behind chronic rhinosinusitis (CRS) has revealed various new endotypes, leading to targeted therapies, especially for severe uncontrolled CRS. Biologics are novel therapeutic strategies providing targeted treatment for the difficult-to-treat recalcitrant CRSwNP patients. Dupilumab is a fully human-derived monoclonal antibody that binds to IL4Rα, inhibiting the signalling of both IL-4 and IL-13.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!